{"disease":{"id":"blasts-more-than-20-percent-of-peripheral-blood-white-cells","name":"blasts more than 20 percent of peripheral blood white cells"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02257138","title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}